A methodology for the analysis of PSA response signatures

Radiotherapy and Oncology

Volumn 98, Issue 2, 2011, Pages 198-202

  Ebert, Martin A ^a,b   Lamb, David S ^c   Joseph, David J ^a,b   Steigler, Allison ^d   Denham, James W ^d  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Progression; Prostate cancer; Prostate specific antigen; Spline fitting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ALGORITHM; ARTICLE; CANCER GROWTH; CLINICAL TRIAL (TOPIC); METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 79951853112     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.11.013     Document Type: Article

References (28)

1. P. Alcantara, A. Hanlon, M.K. Buyyounouski, E.M. Horwitz, and A. Pollack Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death Cancer 109 2007 41 47 (Pubitemid 46120193)
2. J.D. Cox, D.J. Grignon, and R.S. Kaplan Consensus statement: guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041 (Pubitemid 27230027)
3. D.S. Lamb, J.W. Denham, and D.J. Joseph A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96 01 randomized trial. Int J Radiat Oncol Biol Phys 79 2011 385 391
4. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
5. J.W. Denham, A. Steigler, and C. Wilcox Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 115 2009 4477 4487
6. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850 (Pubitemid 41614795)
7. F.A. Critz Time to achieve a prostate specific antigen nadir of 0.2 ng/ml after simultaneous irradiation for prostate cancer J Urol 168 2002 2434 2438 (Pubitemid 35402634)
8. A.L. Hanlon, H. Diratzouian, and G.E. Hanks Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer Int J Radiat Oncol Biol Phys 53 2002 297 303 (Pubitemid 34522096)
9. J.W. Denham, D.S. Lamb, and D. Joseph PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer? Radiother Oncol 90 2009 382 388
10. J.A. Eastham Prostate-specific antigen doubling time as a prognostic marker in prostate cancer Nat Clin Prac Urol 2 2005 482 491 (Pubitemid 41594402)
11. M.J. Shulman, J.A. Karam, and E.A. Benaim Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer Urology 63 2004 732 736 (Pubitemid 38479419)
12. R.S. Svatek, M. Shulman, P.K. Choudhary, and E. Benaim Critical analysis of prostate-specific antigen doubling time calculation methodology Cancer 106 2006 1047 1053
13. G.K. Zagars, and A. Pollack The fall and rise of prostate-specific antigen - kinetics of serum prostate-specific antigen levels after radiation-therapy for prostate-cancer Cancer 72 1993 832 842 (Pubitemid 23215273)
14. J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
15. D.J. Hudson Fitting segmented curves whose join points have to be estimated J Am Stat Assoc 61 1966 1097 1125
16. N.G. Berman, W.K. Wong, S. Bhasin, and E. Ipp Applications of segmented regression models for biomedical studies Am J Physiol Endocrinol Metab 270 1996 E723 E732
17. B. Guess, R. Jennrich, H. Johnson, R. Redheffer, and M. Scholz Using splines to detect changes in PSA doubling times Prostate 54 2003 88 94 (Pubitemid 36120324)
18. J.H. Friedman Multivariate adaptive regression splines Ann Stat 19 1991 1 67
19. C.A. Bellera, J.A. Hanley, L. Joseph, and P.C. Albertsen Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer Ann Epidemiol 18 2008 270 282 (Pubitemid 351406508)
20. K.R. Gabriel Generalised bilinear regression Biometrika 85 1998 689 700
21. C.A. Bellera, J.A. Hanley, L. Joseph, and P.C. Albertsen A statistical evaluation of rules for biochemical failure after radiotherapy in mean treated for prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1357 1363
22. W.H. Press, S.A. Teukolsky, W.T. Vetterling, and B.P. Flannery Numerical recipes: the art of scientific computing 2007 Cambridge University Press Cambridge
23. K. Levenberg A method for the solution of certain nonlinear problems in least squares Quart App Math 2 1944 164 168
24. D. Marquardt An algorithm for least-squares estimation of nonlinear parameters SIAM J App Math 11 1963 431 441
25. R.F. Mould Introductory medical statistics 1998 Institute of Physics Publishing Bristol
26. J.W. Denham, M. Kumar, and P.S. Gleeson Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer Int J Radiat Oncol Biol Phys 74 2009 404 411
27. M. Pinkawa, M.D. Piroth, and R. Holy Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer Radiother Oncol 96 2010 25 29
28. C.C. Parker, and D.P. Dearnaley The management of PSA failure after radical radiotherapy for localized prostate cancer Radiother Oncol 49 1998 103 110 (Pubitemid 29017904)